收费全文 | 82680篇 |
免费 | 6289篇 |
国内免费 | 2909篇 |
耳鼻咽喉 | 378篇 |
儿科学 | 1130篇 |
妇产科学 | 1260篇 |
基础医学 | 12432篇 |
口腔科学 | 1192篇 |
临床医学 | 5617篇 |
内科学 | 12903篇 |
皮肤病学 | 1309篇 |
神经病学 | 10535篇 |
特种医学 | 1059篇 |
外国民族医学 | 37篇 |
外科学 | 5504篇 |
综合类 | 9063篇 |
现状与发展 | 7篇 |
一般理论 | 2篇 |
预防医学 | 2897篇 |
眼科学 | 730篇 |
药学 | 14914篇 |
19篇 | |
中国医学 | 2273篇 |
肿瘤学 | 8617篇 |
2024年 | 180篇 |
2023年 | 1150篇 |
2022年 | 2043篇 |
2021年 | 2840篇 |
2020年 | 2549篇 |
2019年 | 2478篇 |
2018年 | 2533篇 |
2017年 | 2573篇 |
2016年 | 2640篇 |
2015年 | 2927篇 |
2014年 | 4765篇 |
2013年 | 6163篇 |
2012年 | 4620篇 |
2011年 | 5257篇 |
2010年 | 4303篇 |
2009年 | 4313篇 |
2008年 | 4648篇 |
2007年 | 4216篇 |
2006年 | 3634篇 |
2005年 | 3108篇 |
2004年 | 2891篇 |
2003年 | 2657篇 |
2002年 | 2116篇 |
2001年 | 1881篇 |
2000年 | 1667篇 |
1999年 | 1480篇 |
1998年 | 1635篇 |
1997年 | 1484篇 |
1996年 | 1348篇 |
1995年 | 1073篇 |
1994年 | 997篇 |
1993年 | 868篇 |
1992年 | 667篇 |
1991年 | 601篇 |
1990年 | 465篇 |
1989年 | 385篇 |
1988年 | 329篇 |
1987年 | 302篇 |
1986年 | 312篇 |
1985年 | 380篇 |
1984年 | 305篇 |
1983年 | 191篇 |
1982年 | 248篇 |
1981年 | 205篇 |
1980年 | 145篇 |
1979年 | 86篇 |
1978年 | 63篇 |
1977年 | 47篇 |
1976年 | 40篇 |
1975年 | 31篇 |
Introduction
Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. 相似文献Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献